Press Releases

Press Releases

August 7, 2023
SAN DIEGO , Aug. 07, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023 . Second Quarter Highlights: Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8%
July 25, 2023
SAN DIEGO , July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023 , before the market open on Monday, August 7, 2023 . John Aballi , Exagen’s President and Chief Executive
July 24, 2023
SAN DIEGO , July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023 . Mr. Kim currently serves as Chief Financial Officer
May 15, 2023
Record Physician Demand for AVISE® CTD SAN DIEGO , May 15, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN)("Exagen"), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2023 . First Quarter Highlights: Delivered a record 37,312
May 1, 2023
SAN DIEGO , May 01, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patients and partnership activities that enhance the impactful work
April 24, 2023
SAN DIEGO , April 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2023 , after the market close on Monday, May 15, 2023 . John Aballi , Exagen’s President and Chief Executive
March 20, 2023
Record AVISE® CTD Volume in 2022 SAN DIEGO , March 20, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2022 .
Displaying 1 - 10 of 14